Lung Drugs

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better...